IP Library › Granted Patent US 10,385,313
Granted Patent B2
US 10,385,313 · App. 15/026,313 · Granted Aug 20, 2019

Human IPSC-derived vascular-related and hematopoetic cells for therapies and toxicology/drug screenings

Inventors: Manfred Boehm (Bethesda, MD); Guibin Chen (Ellicott City, MD); Mahendra Rao (Timonium, MD); Andre Larochelle (Bethesda, MD)
Assignee: The USA, as represented by the Secretary, Department of Health and Human Services
C12N5/0607C12N5/0018C12N5/0647C12N5/0661C12N5/0662C12N5/0696C12N2500/05C12N2500/30C12N2500/36C12N2500/42C12N2500/44C12N2500/90C12N2501/115C12N2501/155C12N2501/165C12N2501/26C12N2506/03C12N2506/45
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,385,313
App. No.
15/026,313
Granted
Aug 20, 2019
Kind
B2
Abstract

Described herein are cells, cell culture methods, and cell culture media compositions useful for producing and maintaining iPSC-derived cell lines that are of higher purity and maintain cell type integrity better than current iPSC-derived cell lines. Also disclosed are methods of using the described cells and media, such as therapeutic methods of use for the described cells. The described cells include iPSC-derived mesodermal precursor cells (MPC), which itself may differentiate into at least four different cell types. When cultured under appropriate conditions, the mesodermal precursor cells can be used to produce hematopoietic stem cells (HSC), mesenchymal stem cells (MSC), smooth muscle cells (SMC), or unlimited functional endothelial cells (UFEC). One characteristic that makes the described cells desirable is that they can be maintained in culture for a number of days, or passages, without changing phenotype through differentiation.

Claims (22)

1. A cell culture medium consisting essentially of:

Iscove's modified Dulbecco's medium (IMDM),

Ham's F-12 Nutrient Mix, with L-alanyl-L-glutamine additive,

Albumin,

a-monothioglycerol,

protein-free hybridoma mixture II,

L-ascorbic acid 2-phosphate,

L-alanyl-L-glutamine,

Antibiotic,

insulin-transferrin-selenium-ethanolamine supplement,

bone morphogenic protein 4,

vascular endothelial growth factor, and

basic fibroblast growth factor.

2. The cell culture medium of claim 1 , further comprising cholesterol lipids.

3. The cell culture medium of claim 1 , wherein the antibiotic is selected form the group consisting of penicillin, streptomycin and a mixture of penicillin and streptomycin.

4. The cell culture medium of claim 1 , wherein the concentration of albumin, is about 5 mg/ml.

5. The cell culture medium of claim 1 , wherein the concentration of monothioglycerol is from about 350 to about 450 μM.

6. The cell culture medium of claim 1 , wherein the concentration of L-ascorbic acid 2-phosphate is about 50 μg/ml.

7. The cell culture medium of claim 1 , wherein the concentration of L-alanyl-L-glutamine is about 1 mM to about 2 mM.

8. The cell culture medium of claim 1 , wherein the concentration of bone morphogenic protein 4 is about 10 ng/ml.

9. The cell culture medium of claim 1 , wherein the concentration of vascular endothelial growth factor is about 10 ng/ml.

10. The cell culture medium of claim 1 , wherein the concentration of basic fibroblast growth factor is about 10 ng/ml.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 2, 2016
From: BOEHM, MANFRED; CHEN, GUIBIN; RAO, MAHENDRA; LAROCHELLE, ANDRE
To: THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES
Reel/Frame 038434/0133 →
Continuity (2)
Provisional Application 61885209 · Oct 1, 2013
Related Publication 20160222348A1 · Aug 4, 2016